TGFB1 and cancer: In this review, we will (i) discuss the pathophysiology of the TGF-β signaling pathway with regards to cancer progression and evidence of ICI resistance, (ii) discuss the pre-clinical and clinical evidence supporting the combination of ICI with TGF-β inhibitors to overcome resistance, and (iii) examine current ongoing clinical trials using this combination treatment and propose future directions.